## Brian J Stockman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6473005/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NMR-Based Activity Assays for Determining Compound Inhibition, IC <sub>50</sub> Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases. Journal of Visualized Experiments, 2019, , .	0.3	1
2	Discovery of Ligand-Efficient Scaffolds for the Design of Novel <i>Trichomonas vaginalis</i> Uridine Nucleoside Ribohydrolase Inhibitors Using Fragment Screening. ACS Omega, 2019, 4, 16226-16232.	3.5	5
3	Ligand-Efficient Inhibitors of <i>Trichomonas vaginalis</i> Adenosine/Guanosine Preferring Nucleoside Ribohydrolase. ACS Infectious Diseases, 2019, 5, 345-352.	3.8	8
4	Structureâ€activity relationships of fragmentâ€based inhibitors of Trichomonas vaginalis adenosine/guanosine preferring nucleoside ribohydrolase. FASEB Journal, 2019, 33, 470.3.	0.5	0
5	Translation of 1 H and 19 F NMRâ€based activity assays to in vitro characterization of nucleoside hydrolase activity in cell extracts and whole cells. FASEB Journal, 2019, 33, .	0.5	0
6	Druggability of the guanosine/adenosine/cytidine nucleoside hydrolase from <i>Trichomonas vaginalis</i> . Chemical Biology and Drug Design, 2018, 92, 1736-1742.	3.2	13
7	NMR-Based Activity Assays To Characterize Enzymes in the Biochemistry Laboratory and in Undergraduate Research. ACS Symposium Series, 2016, , 33-52.	0.5	0
8	Student-Led Engagement of Journal Article Authors in the Classroom Using Web-Based Videoconferencing. Journal of Chemical Education, 2015, 92, 120-123.	2.3	4
9	Adenosine/guanosine preferring nucleoside ribohydrolase is a distinct, druggable antitrichomonal target. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5036-5039.	2.2	12
10	Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1080-1084.	2.2	27
11	Design and Characterization of a Zn2+-Binding Four-Helix Bundle Protein in the Biophysical Chemistry Laboratory. Journal of Chemical Education, 2014, 91, 451-454.	2.3	8
12	SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. Journal of Biological Chemistry, 2010, 285, 8340-8351.	3.4	794
13	Resonance assignments for stromelysin complexed with a β-sulfonyl hydroxamate inhibitor. Biomolecular NMR Assignments, 2009, 3, 183-186.	0.8	0
14	Identification of Allosteric PIFâ€Pocket Ligands for PDK1 using NMRâ€Based Fragment Screening and <sup>1</sup> Hâ€ <sup>15</sup> N TROSY Experiments. Chemical Biology and Drug Design, 2009, 73, 179-188.	3.2	55
15	2-Fluoro-ATP as a Versatile Tool for <sup>19</sup> F NMR-Based Activity Screening. Journal of the American Chemical Society, 2008, 130, 5870-5871.	13.7	36
16	A Nuclear Magnetic Resonance–Based Functional Assay for Nicotinamide Adenine Dinucleotide Synthetase. Journal of Biomolecular Screening, 2007, 12, 457-463.	2.6	3
17	Fluorine-NMR Experiments for High-Throughput Screening:Â Theoretical Aspects, Practical Considerations, and Range of Applicability. Journal of the American Chemical Society, 2003, 125, 7696-7703.	13.7	235
18	1 H Nuclear Magnetic Resonance Study of Oxazolidinone Binding to Bacterial Ribosomes. Antimicrobial Agents and Chemotherapy, 2002, 46, 625-629.	3.2	57

BRIAN J STOCKMAN

#	Article	IF	CITATIONS
19	Screening of Compound Libraries for Protein Binding Using Flow-Injection Nuclear Magnetic Resonance Spectroscopy. Methods in Enzymology, 2002, 338, 230-246.	1.0	15
20	High-Throughput NMR-Based Screening with Competition Binding Experiments. Journal of the American Chemical Society, 2002, 124, 7702-7709.	13.7	162
21	NMR screening techniques in drug discovery and drug design. Progress in Nuclear Magnetic Resonance Spectroscopy, 2002, 41, 187-231.	7.5	198
22	Physical methods to determine the binding mode of putative ligands for hepatitis C virus NS3 helicase. Analytical Biochemistry, 2002, 309, 186-195.	2.4	11
23	Fluorine-NMR Competition Binding Experiments for High-Throughput Screening of Large Compound Mixtures. Combinatorial Chemistry and High Throughput Screening, 2002, 5, 605-611.	1.1	77
24	WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. Journal of Biomolecular NMR, 2001, 21, 349-359.	2.8	472
25	An NMR study of conformations of substituted dipeptides in dodecylphosphocholine micelles: Implications for drug transport. Biopolymers, 2000, 53, 396-410.	2.4	14
26	Dynamics of stromelysin/inhibitor interactions studied by 15N NMR relaxation measurements: comparison of ligand binding to the S1-S3 and S'1-S'3 subsites. Journal of Biomolecular NMR, 1999, 15, 55-64.	2.8	34
27	Thermodynamic and circular dichroism studies differentiate inhibitor interactions with the stromelysin S1–S3 and S′1–S′3 subsites. BBA - Proteins and Proteomics, 1999, 1434, 304-316.	2.1	5
28	NMR spectroscopy as a tool for structure-based drug design. Progress in Nuclear Magnetic Resonance Spectroscopy, 1998, 33, 109-151.	7.5	41
29	Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Science, 1998, 7, 2281-2286.	7.6	31
30	1H and 15N NMR resonance assignments and solution secondary structure of oxidized Desulfovibrio desulfuricans flavodoxin. Journal of Biomolecular NMR, 1996, 7, 225-35.	2.8	5
31	Purification and structural characterization of the CD11b/CD18 integrin α subunit I domain reveals a folded conformation in solution. FEBS Letters, 1995, 369, 197-201.	2.8	8
32	Solution structure of human interleukin-1 receptor antagonist protein. FEBS Letters, 1994, 349, 79-83.	2.8	15
33	Structural changes caused by site-directed mutagenesis of tyrosine-98 in Desulfovibrio vulgaris flavodoxin delineated by 1H and 15N NMR spectroscopy: implications for redox potential modulation. Biochemistry, 1994, 33, 15298-15308.	2.5	39
34	1H and 15N resonance assignments and solution secondary structure of oxidized Desulfovibrio vulgaris flavodoxin determined by heteronuclear three-dimensional NMR spectroscopy. Journal of Biomolecular NMR, 1993, 3, 133-49.	2.8	13
35	Heteronuclear three-dimensional NMR spectroscopy of a partially denatured protein: The A-state of human ubiquitin. Journal of Biomolecular NMR, 1993, 3, 285-296.	2.8	88
36	NMR analysis of ligand binding. Current Opinion in Structural Biology, 1992, 2, 52-56.	5.7	4

3

BRIAN J STOCKMAN

#	Article	IF	CITATIONS
37	Secondary structure and topology of interleukin-1 receptor antagonist protein determined by heteronuclear three-dimensional NMR spectroscopy. Biochemistry, 1992, 31, 5237-5245.	2.5	44
38	Structure of the oxidized long hain flavodoxin from anabaena 7120 at 2 å resolution. Protein Science, 1992, 1, 1413-1427.	7.6	102
39	Proton, carbon, and nitrogen chemical shifts accurately delineate differences and similarities in secondary structure between the homologous proteins IRAP and IL-1β. Journal of Biomolecular NMR, 1992, 2, 591-596.	2.8	9
40	NMR studies of structure and dynamics of isotope enriched proteins. Biopolymers, 1992, 32, 381-390.	2.4	12
41	Methotrexate binds in a non-productive orientation to human dihydrofolate reductase in solution, based on NMR spectroscopy. FEBS Letters, 1991, 283, 267-269.	2.8	14
42	Hydrogen-1, carbon-13, and nitrogen-15 NMR spectroscopy of Anabaena 7120 flavodoxin: assignment of .betasheet and flavin binding site resonances and analysis of protein-flavin interactions. Biochemistry, 1990, 29, 9600-9609.	2.5	46
43	Redox and spectral properties of flavodoxin from Anabaena 7120. Archives of Biochemistry and Biophysics, 1990, 280, 68-73.	3.0	32
44	Flavodoxin from Anabaena 7120: uniform nitrogen-15 enrichment and hydrogen-1, nitrogen-15, and phosphorus-31 NMR investigations of the flavin mononucleotide binding site in the reduced and oxidized states. Biochemistry, 1988, 27, 136-142.	2.5	49